A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function
Open Access
- 21 September 2021
- journal article
- research article
- Published by Elsevier BV in Kidney International
- Vol. 101 (1), 174-184
- https://doi.org/10.1016/j.kint.2021.09.005
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion InjuryPLOS ONE, 2016
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trialEuropean Heart Journal, 2016
- A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney InjuryAmerican Journal of Kidney Diseases, 2015
- Acute SGLT inhibition normalizes O2tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic ratsAmerican Journal of Physiology-Renal Physiology, 2015
- SAS Macro for Causal Mediation Analysis with Survival DataEpidemiology, 2015
- Do Tubular Changes in the Diabetic Kidney Affect the Susceptibility to Acute Kidney Injury?Nephron Clinical Practice, 2014
- World Incidence of AKIClinical Journal of the American Society of Nephrology, 2013
- Chronic kidney disease after acute kidney injury: a systematic review and meta-analysisKidney International, 2012
- Acute Kidney Injury Episodes and Chronic Kidney Disease Risk in Diabetes MellitusClinical Journal of the American Society of Nephrology, 2011
- Causal Mediation Analysis With Survival DataEpidemiology, 2011